The Align Foundation, in partnership with NIST, has built a publicly available platform to advance protein sequence-to-function prediction. We are generating standardized functional data for hundreds of thousands of protein variants across diverse functions using our scalable, growth-based quantitative sequencing platform (GROQ-seq). With seven functions onboarded and multiple academic and facility partners, this growing resource is a coordinated field-wide effort to improve functional prediction models and benchmark library design strategies.

Titering of baculovirus stocks is a vital and necessary step in good protein production, though it is often subjective and/or time consuming and tedious. This newly developed cell line, aims to address the issues many of the current day titering techniques and offer a rapid, accurate method for obtaining viral stock titers.

BigHat Biosciences discovery platform couples AI antibody design with a high speed wet lab that enables rapid, iterative screening of thousands of antibodies per week. Powered by a custom cell-free protein synthesis system, our platform enables optimization across multiple axes of antibody properties including affinity, function, and developability. We’ll highlight key developments of our CFPS system, including reagent manufacturing, template construction, and reaction conditions which enable robust antibody characterization of in silico designs in the wet lab. We’ll also share some case studies of how our platform has been used to optimize increasingly complex multi-objective design challenges for next-generation antibody therapeutics.

• Transient or Stable Pool or Both? Smart choices for rapid discovery process           
• High throughput Protein Production: Integrating digital pipelines with lab automation
• Leveraging AI to accelerate and improve the efficiency of protein production​

The presentation explores the end-to-end process of therapeutic antibody discovery and development, highlighting challenges across key stages. How internal and external innovations have driven antibody discovery, expression and development. From candidate selection, antibody humanisation, expression systems, cell line engineering and microfluidic cell sorting. Together, these technologies have provided critical advancements to antibody-based therapeutics.

Novel labware, integrated automation, and optimized workflows now enable efficient, high-throughput production and purification of antibodies at multi-milligram scales. Recent advances remove long-standing bottlenecks in harvesting and purifying harder to express antibody formats from mid-scale cultures, supporting seamless, end-to-end automation. These innovations accelerate discovery and development pipelines, advancing the automated manufacture of complex biologics previously limited by labor-intensive manual processes.

Complex multi-pass membrane proteins, including GPCRs and cancer-associated targets, are essential mediators of physiology and promising therapeutic candidates, yet their expression and stabilization remain difficult. Their hydrophobic transmembrane regions demand a precise lipid environment, often leading to misfolding, aggregation, degradation, and low yields in heterologous systems, limiting their use in antibody discovery, structural biology, and functional assays. Here we present a reliable nanodisc-based workflow that enables milligram-scale production of soluble, properly folded membrane proteins in a single cycle. The resulting nanodiscs preserve native conformation and epitopes, and the method is applicable to multi-pass targets across mammalian and insect expression platforms.

Built upon 15 years of research, the platform optimized DNA to increase expression titers. The platform considers all aspects of protein production and is based on a unique combination of approaches such as biophysical modeling, molecular evolution, and AI. In dozens of cases, we have achieved high titers, providing a reliable solution for complex protein synthesis.

Despite recent advances in our understanding of genetic features that promote robust protein expression, transgenes in biotechnology have remained largely unchanged for decades. Natural human genes are rich in intron sequences that can drive these crucial expression benefits, but were previously difficult to replicate in artificial transgenes. At ExpressionEdits, we're changing this by deciphering ‘genetic syntax’ using high-throughput screening and machine learning to design intronized transgenes with improved protein expression.

Systematic comparison of mammalian codon optimization methods based in common/rare codon usage, RNA stability, and oligo assembly efficiency of 21 human and murine proteins lead to surprising conclusion that extensive codon optimization is not necessary for homologous recombinant protein expression in mammalian cells.

Leveraging regulatory elements such as re-engineered promoters and optimized terminator polyA sequences can significantly enhance protein yields. By strengthening promoter activity, transcription initiation is increased, while improved polyA terminators ensure efficient mRNA processing and stability. Together, these modifications boost gene expression, leading to higher protein production. This approach is valuable in biotechnology and therapeutic protein manufacturing, where maximizing protein output is essential for cost-effective and scalable production